IDEAS home Printed from https://ideas.repec.org/a/spr/pharme/v35y2017i12d10.1007_s40273-017-0558-5.html
   My bibliography  Save this article

Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation

Author

Listed:
  • Eddie Gibson

    (Wickenstones Ltd)

  • Ian Koblbauer

    (Wickenstones Ltd)

  • Najida Begum

    (Wickenstones Ltd)

  • George Dranitsaris

    (Augmentium Pharma Consulting Inc.)

  • Danny Liew

    (Monash University)

  • Phil McEwan

    (Health Economics and Outcomes Research Ltd)

  • Amir Abbas Tahami Monfared

    (Bristol-Myers Squibb
    McGill University)

  • Yong Yuan

    (Bristol-Myers Squibb)

  • Ariadna Juarez-Garcia

    (Bristol-Myers Squibb)

  • David Tyas

    (Bristol-Myers Squibb)

  • Michael Lees

    (Bristol-Myers Squibb)

Abstract

Background New immuno-oncology (I-O) therapies that harness the immune system to fight cancer call for a re-examination of the traditional parametric techniques used to model survival from clinical trial data. More flexible approaches are needed to capture the characteristic I-O pattern of delayed treatment effects and, for a subset of patients, the plateau of long-term survival. Objectives Using a systematic approach to data management and analysis, the study assessed the applicability of traditional and flexible approaches and, as a test case of flexible methods, investigated the suitability of restricted cubic splines (RCS) to model progression-free survival (PFS) in I-O therapy. Methods The goodness of fit of each survival function was tested on data from the CheckMate 067 trial of monotherapy versus combination therapy (nivolumab/ipilimumab) in metastatic melanoma using visual inspection and statistical tests. Extrapolations were validated using long-term data for ipilimumab. Results Modelled PFS estimates using traditional methods did not provide a good fit to the Kaplan–Meier (K–M) curve. RCS estimates fit the K–M curves well, particularly for the plateau phase. RCS with six knots provided the best overall fit, but RCS with one knot performed best at the plateau phase and was preferred on the grounds of parsimony. Conclusions RCS models represent a valuable addition to the range of flexible approaches available to model survival when assessing the effectiveness and cost-effectiveness of I-O therapy. A systematic approach to data analysis is recommended to compare the suitability of different approaches for different diseases and treatment regimens.

Suggested Citation

  • Eddie Gibson & Ian Koblbauer & Najida Begum & George Dranitsaris & Danny Liew & Phil McEwan & Amir Abbas Tahami Monfared & Yong Yuan & Ariadna Juarez-Garcia & David Tyas & Michael Lees, 2017. "Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation," PharmacoEconomics, Springer, vol. 35(12), pages 1257-1270, December.
    • Handle: RePEc:spr:pharme:v:35:y:2017:i:12:d:10.1007_s40273-017-0558-5
    DOI: 10.1007/s40273-017-0558-5
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40273-017-0558-5
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s40273-017-0558-5?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Patrick Royston & Paul C. Lambert, 2011. "Flexible Parametric Survival Analysis Using Stata: Beyond the Cox Model," Stata Press books, StataCorp LP, number fpsaus, March.
    2. Patrick Royston, 2001. "Flexible alternatives to the Cox model, and more," Stata Journal, StataCorp LP, vol. 1(1), pages 1-28, November.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Deborah Plana & Geoffrey Fell & Brian M. Alexander & Adam C. Palmer & Peter K. Sorger, 2022. "Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects," Nature Communications, Nature, vol. 13(1), pages 1-13, December.
    2. Bengt Jönsson & Grace Hampson & Jonathan Michaels & Adrian Towse & J.-Matthias Graf Schulenburg & Olivier Wong, 2019. "Advanced therapy medicinal products and health technology assessment principles and practices for value-based and sustainable healthcare," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(3), pages 427-438, April.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Jackson, Christopher, 2016. "flexsurv: A Platform for Parametric Survival Modeling in R," Journal of Statistical Software, Foundation for Open Access Statistics, vol. 70(i08).
    2. Enzo Coviello, 2009. "Covariate-adjusted cumulative incidence in the presence of competing risks," Italian Stata Users' Group Meetings 2009 02, Stata Users Group.
    3. Patrick Royston, 2012. "Tools to simulate realistic censored survival-time distributions," Stata Journal, StataCorp LP, vol. 12(4), pages 639-654, December.
    4. Noori Akhtar-Danesh, 2015. "A Comparison of Modeling Scales in Flexible Parametric Models," 2015 Stata Conference 15, Stata Users Group.
    5. Martin Gaksch & Rolf Jorde & Guri Grimnes & Ragnar Joakimsen & Henrik Schirmer & Tom Wilsgaard & Ellisiv B Mathiesen & Inger Njølstad & Maja-Lisa Løchen & Winfried März & Marcus E Kleber & Andreas Tom, 2017. "Vitamin D and mortality: Individual participant data meta-analysis of standardized 25-hydroxyvitamin D in 26916 individuals from a European consortium," PLOS ONE, Public Library of Science, vol. 12(2), pages 1-15, February.
    6. Talamas Marcos, Miguel Ángel, 2023. "Surviving Competition: Neighborhood Shops vs. Convenience Chains," IDB Publications (Working Papers) 13018, Inter-American Development Bank.
    7. Iversen, Tor & Ching-to , Albert Ma, 2020. "Technology Adoption in Primary Health Care," HERO Online Working Paper Series 2020:4, University of Oslo, Health Economics Research Programme.
    8. Patrick Royston, 2007. "Profile likelihood for estimation and confidence intervals," Stata Journal, StataCorp LP, vol. 7(3), pages 376-387, September.
    9. Herrera Dappe,Matias & Melecky,Martin & Turkgulu,Burak, 2022. "Fiscal Risks from Early Termination of Public-Private Partnerships in Infrastructure," Policy Research Working Paper Series 9972, The World Bank.
    10. Michael J. Crowther & Paul C. Lambert, 2012. "Simulating complex survival data," Stata Journal, StataCorp LP, vol. 12(4), pages 674-687, December.
    11. James P Cross & AustÄ— VaznonytÄ—, 2020. "Can we do what we say we will do? Issue salience, government effectiveness, and the legislative efficiency of Council Presidencies," European Union Politics, , vol. 21(4), pages 657-679, December.
    12. Martin Connock & Peter Auguste & Xavier Armoiry, 2021. "A comparison of published time invariant Markov models with Partitioned Survival models for cost effectiveness estimation; three case studies of treatments for glioblastoma multiforme," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 22(1), pages 89-100, February.
    13. Anne J Rerimoi & Momodou Jasseh & Schadrac C Agbla & Georges Reniers & Anna Roca & Ian M Timæus, 2019. "Under-five mortality in The Gambia: Comparison of the results of the first demographic and health survey with those from existing inquiries," PLOS ONE, Public Library of Science, vol. 14(7), pages 1-14, July.
    14. Jonathan Karnon & Orla Caffrey & Clarabelle Pham & Richard Grieve & David Ben‐Tovim & Paul Hakendorf & Maria Crotty, 2013. "Applying Risk Adjusted Cost‐Effectiveness (Rac‐E) Analysis To Hospitals: Estimating The Costs And Consequences Of Variation In Clinical Practice," Health Economics, John Wiley & Sons, Ltd., vol. 22(6), pages 631-642, June.
    15. Paul Lambert, 2018. "Standardized survival curves and related measures from flexible survival parametric models," London Stata Conference 2018 14, Stata Users Group.
    16. Nan Liu, 2021. "Market buoyancy, information transparency and pricing strategy in the Scottish housing market," Urban Studies, Urban Studies Journal Limited, vol. 58(16), pages 3388-3406, December.
    17. Amin Moniri-Morad & Mohammad Pourgol-Mohammad & Hamid Aghababaei & Javad Sattarvand, 2019. "Reliability-based covariate analysis for complex systems in heterogeneous environment: Case study of mining equipment," Journal of Risk and Reliability, , vol. 233(4), pages 593-604, August.
    18. Patricia Guyot & Anthony E. Ades & Matthew Beasley & Béranger Lueza & Jean-Pierre Pignon & Nicky J. Welton, 2017. "Extrapolation of Survival Curves from Cancer Trials Using External Information," Medical Decision Making, , vol. 37(4), pages 353-366, May.
    19. Zuzana Špacírová & Stephen Kaptoge & Leticia García-Mochón & Miguel Rodríguez Barranco & María José Sánchez Pérez & Nicola P. Bondonno & Anne Tjønneland & Elisabete Weiderpass & Sara Grioni & Jaime Es, 2023. "The cost-effectiveness of a uniform versus age-based threshold for one-off screening for prevention of cardiovascular disease," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 24(7), pages 1033-1045, September.
    20. H. Joseph Newton & Nicholas J. Cox, 2016. "The Stata Journal Editors' Prize 2016: Patrick Royston," Stata Journal, StataCorp LP, vol. 16(4), pages 815-825, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:pharme:v:35:y:2017:i:12:d:10.1007_s40273-017-0558-5. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.